M. Felices

发表

Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection

L. Nguyen, X. Declèves, B. Pasquiers, 2022, International journal of molecular sciences.

Impact of Adding Enfuvirtide to the Predictive Value of the Darunavir Genotypic Resistance Score

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2011, Journal of acquired immune deficiency syndromes.

Predictors and Outcomes of HIV-Infected Antiretroviral-Naive Patients With Discordant Responses to Combination Antiretroviral Treatment in Asian and Australian Populations : Results From APHOD

V. Calvez, G. Peytavin, D. Descamps, 2011 .

Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method

J. Ouédraogo, A. Djimde, S. Sirima, 2019, Scientific Reports.

Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies

M. A. Bray, Els Torreele, Michael A. Bray, 2014, Clinical Pharmacokinetics.

Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation

A. Bacchieri, C. Funck-Brentano, S. Duparc, 2019, Scientific Reports.

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.

V. Calvez, F. Brun-Vézinet, C. Katlama, 2009, The Journal of antimicrobial chemotherapy.

Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study

A. Tarral, S. Blesson, Sophie Delhomme, 2023, Clinical Pharmacokinetics.

A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years

E. Jurkiewicz, P. Bourrinet, M. Koob, 2017, Investigative radiology.

Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method

J. Ouédraogo, A. Djimde, S. Sirima, 2019, Scientific Reports.

Comparative Bioavailability of Two Oral Nimodipine Formulations after Administration to 24 Healthy Volunteers

M. Guillaume, A. Alcaide, V. Gualano, 1999 .

Randomized study of the effect of gadopiclenol, a new gadolinium‐based contrast agent, on the QTc interval in healthy subjects

C. Funck-Brentano, P. Desché, N. Le Fur, 2020, British journal of clinical pharmacology.

Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus

J. Dubourg, S. Bolze, P. Fouqueray, 2020, European Journal of Clinical Pharmacology.

Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies Antoine TarralSeverine BlessonOlaf Valverde Mordt • Els TorreeleDaniela SassellaMichael A. BrayLionel Hovsepian • Eric EveneVirginie GualanoMathie

M. A. Bray, A. Tarral, S. Blesson, 2014 .

Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation

A. Bacchieri, C. Funck-Brentano, S. Duparc, 2019, Scientific Reports.